Scholarlink

Background <p>Retinoblastoma (RB) lacks effective targeted therapies. Super-enhancers (SEs) are crucial for tumorigenesis, yet their role in RB was unclear.</p> Methods <p>We profiled active SEs in RB cells using chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq). qRT-PCR, single-cell RNA sequencing (scRNA-Seq) and immunohistochemistry (IHC) were employed to identify the critical regulator of SE activity. The anti-tumour effect of targeted blockade of SE regulator, achieved via pharmacological degradation and specific lentiviruses, was investigated in vitro and in preclinical models of subcutaneous, intraocular, and central nervous system (CNS)-metastatic RB.</p> Results <p>Cyclin-dependent kinase 12 (CDK12) was identified as a key SE regulator. SE-driven oncogenic transcription was suppressed by CDK12 inhibition, leading to eliminated tumour outgrowth and metastasis. In addition, SE-associated oncogenes <i>BIRC5</i> and <i>PTPRC</i> were identified as essential for RB cell survival and stemness. Furthermore, <i>PTPRC</i> overexpression rescued the anti-tumour effect of BSJ-4-116.</p> Conclusions <p>This study defines CDK12 as a master regulator of oncogenic SEs in RB. Targeting the CDK12-SE axis, via CDK12 or downstream effectors like <i>BIRC5</i>/<i>PTPRC</i>, presents a novel therapeutic strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Super-enhancer landscape regulated by CDK12 drives retinoblastoma progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Caiyao Guo,
  • Wei Dai,
  • Jingxuan Li,
  • Xuan Zhou,
  • Jianqiong Yang,
  • Fenfen Xie,
  • Wan Liang,
  • Jingfeng Zhou,
  • Wen Hou,
  • Jinxia Lan,
  • Hai Liu,
  • Shenglan Liu

摘要

Background

Retinoblastoma (RB) lacks effective targeted therapies. Super-enhancers (SEs) are crucial for tumorigenesis, yet their role in RB was unclear.

Methods

We profiled active SEs in RB cells using chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq). qRT-PCR, single-cell RNA sequencing (scRNA-Seq) and immunohistochemistry (IHC) were employed to identify the critical regulator of SE activity. The anti-tumour effect of targeted blockade of SE regulator, achieved via pharmacological degradation and specific lentiviruses, was investigated in vitro and in preclinical models of subcutaneous, intraocular, and central nervous system (CNS)-metastatic RB.

Results

Cyclin-dependent kinase 12 (CDK12) was identified as a key SE regulator. SE-driven oncogenic transcription was suppressed by CDK12 inhibition, leading to eliminated tumour outgrowth and metastasis. In addition, SE-associated oncogenes BIRC5 and PTPRC were identified as essential for RB cell survival and stemness. Furthermore, PTPRC overexpression rescued the anti-tumour effect of BSJ-4-116.

Conclusions

This study defines CDK12 as a master regulator of oncogenic SEs in RB. Targeting the CDK12-SE axis, via CDK12 or downstream effectors like BIRC5/PTPRC, presents a novel therapeutic strategy.